This latter result is consistent with previous findings from our laboratory demonstrating an enhancer switch in the AGR2 gene in this tamoxifen-resistant tumor model, thereby reducing the dependence of AGR2 expression on ER activity [14]. This evidence concerns the gene AGR2 and neoplasm.